Logo

Celltrion Reports Results of CT-P13 SC (biosimilar- infliximab) in a Clinical Study for Rheumatoid Arthritis #EULAR2019

Share this
Celltrion Reports Results of CT-P13 SC (biosimilar- infliximab) in a Clinical Study for Rheumatoid Arthritis #EULAR2019

Celltrion Reports Results of CT-P13 SC (biosimilar- infliximab) in a Clinical Study for Rheumatoid Arthritis #EULAR2019

Shots:

  • The study results involves assessing of CT-P13 SC (90mg/120mg/180mg) vs CT-P13 IV (3mg/kg)  in 50 patients in ratio (1:1:1:1) with RA- followed by a P-I/III study assessing CT-P13 SC (120mg- q2w) vs CT-P13 IV in 362 patients in ratio (1:1) with RA for 30wks.
  • Collective results: @54wks. efficacy is comparable; DAS28 (CRP) and ACR20 are comparable in all cohorts; CT-P13 SC is non-inferior to CT-P13 IV- @22wks. similar ACR response- @6wk. SC 120mg safety is comparable to IV dose
  • CT-P13 is a mAb- currently being evaluated in an additional 5yrs. study for RA and ankylosing spondylitis and has received approval in the US (marketed as Inflectra) in Apr’16- in Europe (marketed as Remsima) in Sept’13- additionally in other 89+ countries

Ref: BusinessWire | Image: Celltrion

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions